Uninterrupted edoxaban versus vitamin k antagonists for ablation of atrial fibrillation:the ELIMINATE-AF Trial

18 March 2019 (14:00 - 14:10)

Organised by:

Video

Sign in for access options

Slides

About the speaker

Professor Stefan H Hohnloser

Johann Wolfgang Goethe University, Frankfurt (Germany)

10 More presentations in this session

Presentation thumbnail

ELIMINATE-AF Trial - Discussion

Professor T. Potpara (Belgrade, RS)

Presentation thumbnail

Internal vs. external electrical cardioversion of atrial arrhythmias in patients with an implantable cardioverter-defibrillator: a randomised controlled clinical trial

Doctor J. Luker (Cologne, DE)

Presentation thumbnail

Internal vs. external electrical cardioversion of atrial arrhythmias in patients with an implantable cardioverter-defibrillator: a randomised controlled clinical trial - Discussion

Professor I. Van Gelder (Groningen, NL)

Presentation thumbnail

Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve.

Miss L. Melgaard (Aalborg, DK)

Presentation thumbnail

Thromboembolic risk in patients with atrial fibrillation and valvular heart disease according to the EHRA Type 2 definition: beyond mitral stenosis and mechanical prosthetic heart valve - Discussion

Professor P. Kirchhof (Hamburg, DE)

Access the full session

Session thumbnail

Late-breaking trials 3

The Event

EHRA 2019

18 March 2019 14:00 CET

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

Congress Session

Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources